Homology Medicines, Inc., a Bedford, Mass.-based genetic medicines company translating proprietary gene editing and gene therapy technologies into novel treatments for patients, closed an $83.5m Series B financing. The round was led by Deerfield Management with participation from new investors Fidelity Management and Research Company, HBM Healthcare Investments, Maverick Ventures, Novartis, Rock Springs Capital, Vida Ventures, Vivo Capital and Alexandria Venture Investments and existing investors 5AM Ventures, ARCH Venture Partners and Temasek. In conjunction with the financing, Homology has appointed Cam Wheeler and Mahendra Shah, Ph.D., Managing Director at Vivo Capital, to its Board of Directors.